2 news items
Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b 'ASCEND-NASH' Trial
HEPA
19 Apr 24
biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial
HEPA
19 Apr 24
"), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic
- Prev
- 1
- Next